BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21764752)

  • 1. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
    Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD
    Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
    Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
    Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
    PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
    Chou FS; Griesinger A; Wunderlich M; Lin S; Link KA; Shrestha M; Goyama S; Mizukawa B; Shen S; Marcucci G; Mulloy JC
    Blood; 2012 Jul; 120(4):709-19. PubMed ID: 22337712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
    Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
    Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
    Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
    Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
    Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
    Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
    Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
    Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
    Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pontin is a critical regulator for AML1-ETO-induced leukemia.
    Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
    Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
    Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
    Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
    Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
    Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.